Edgewise Therapeutics, Inc. EWTX Debt-to-equity

Debt-to-equity at other companies

Bristol-Myers SquibbBMY

1.9×-0.9×

Sarepta Therapeutics, Inc.SRPT

0.1×0.0×

CytokineticsCYTK

2.2×—

Dyne Therapeutics, Inc.DYN

0.2×+0.2×

Solid Biosciences Inc.SLDB

0.1×0.0×

Capricor TherapeuticsCAPR

0.1×0.0×

FAQ

What is Edgewise Therapeutics, Inc.'s debt-to-equity?

Edgewise Therapeutics, Inc. (EWTX) reported debt-to-equity of 0× in Q1 2026.

How has Edgewise Therapeutics, Inc.'s debt-to-equity changed year-over-year?

Edgewise Therapeutics, Inc.'s debt-to-equity decreased by 27.4% year-over-year, from 0× to 0×.

What is the long-term trend for Edgewise Therapeutics, Inc.'s debt-to-equity?

Over 3 years (2022 to 2025), Edgewise Therapeutics, Inc.'s debt-to-equity has grown at a -15.7% compound annual growth rate (CAGR), from 0× to 0×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.